Esperion Therapeutics (ESPR) Current Deferred Revenue (2019 - 2026)

Esperion Therapeutics' Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $43.5 million for Q1 2026.

• Quarterly Current Deferred Revenue rose 858.41% year-over-year to $43.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.5 million (up 858.41% YoY) and the FY2025 annual result came in at $34.5 million, up 304.75% from the prior year.
• Current Deferred Revenue was $43.5 million for Q1 2026 at Esperion Therapeutics, up from $34.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $43.5 million in Q1 2026 and bottomed at $3.5 million in Q4 2022.
• A 5-year average of $17.6 million and a median of $15.6 million in 2023 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2025 — Current Deferred Revenue plunged 84.52% — and 2026, when it surged 858.41%.
• Esperion Therapeutics' Current Deferred Revenue stood at $3.5 million in 2022, then jumped by 624.32% to $25.4 million in 2023, then tumbled by 66.47% to $8.5 million in 2024, then jumped by 304.75% to $34.5 million in 2025, then rose by 26.26% to $43.5 million in 2026.
• Business Quant data shows ESPR's Current Deferred Revenue at $43.5 million in Q1 2026, $34.5 million in Q4 2025, and $30.7 million in Q3 2025.